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Objectives The purpose of this study was to determine the extent to which effectiveness of cardiac and diabetes treatment
strategies varies by patient age.
Background The impact of age on the effectiveness of revascularization and hyperglycemia treatments has not been thor-
oughly investigated.
Methods In the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial, 2,368 patients with doc-
umented stable heart disease and type 2 diabetes were randomized to receive prompt revascularization versus initial
medical therapy with deferred revascularization and insulin sensitization versus insulin provision for hyperglycemia
treatment. Patients were followed for an average of 5.3 years. Cox regression and mixed models were used to investi-
gate the effect of age and randomized treatment assignment on clinical and health status outcomes.
Results The effect of prompt revascularization versus medical therapy did not differ by age for death (interaction p 
0.99), major cardiovascular events (interaction p  0.081), angina (interaction p  0.98), or health status out-
comes. After intervention, participants of all ages had significant angina and health status improvement.
Younger participants experienced a smaller decline in health status during follow-up than older participants (age
by time interaction p  0.01). The effect of the randomized glycemia treatment on clinical and health status
outcomes was similar for patients of different ages.
Conclusions Among patients with stable heart disease and type 2 diabetes, the relative beneficial effects of a strategy of prompt
revascularization versus initial medical therapy and insulin-sensitizing versus insulin-providing therapy on clinical end-
points, symptom relief, and perceived health status outcomes do not vary by age. Health status improved significantly
after treatment for all ages, and this improvement was sustained longer among younger patients. (Bypass Angio-
plasty Revascularization Investigation in Type 2 Diabetes [BARI 2D]; NCT00006305) (J Am Coll Cardiol 2011;58:
810–9) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.020The effectiveness of coronary revascularization among older
patients remains controversial. Concerns exist about higher
procedural risk and lower long-term effectiveness in the
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August 16, 2011:810–9 Age Study in the BARI 2D Trialapproach was shown to achieve a similar survival advantage
for older and younger patients (2,3). However, in practice,
older patients tend to receive less intensive treatment.
Studies based on population registries found that patients
with heart disease suitable for revascularization were less
likely to undergo revascularization than younger patients
(4,5). Another area of concern is that the prevalence of
chronic conditions, such as heart disease, hypertension, and
type 2 diabetes, increases with age (6). As most treatment
protocols are designed to focus on a specific chronic condi-
tion, the optimal clinical approach to manage comorbidities
simultaneously is not clear.
The BARI 2D (Bypass Angioplasty Revascularization
Investigation Type 2 Diabetes) trial is a randomized clinical
trial that evaluated the treatment strategies for patients with
documented stable ischemic heart disease and type 2 diabe-
tes. The main finding of the BARI 2D was that a treatment
strategy of prompt revascularization or medical therapy for
heart disease and a treatment strategy of insulin sensitiza-
tion or insulin provision for type 2 diabetes resulted in
similar rates of all-cause mortality and major cardiovascular
events (7), whereas prompt revascularization was associated
with modest improvement in angina relief and small but
significant benefits in health status (8). Age was one of the
pre-specified subgroup factors in the BARI 2D that might
alter clinical outcomes. The present study investigated
whether 1 treatment strategy would be especially advanta-
geous for older patients and examined the primary hypoth-
esis: whether the effectiveness of the randomized treatment
strategies for ischemic heart disease differed by age. Treat-
ment effectiveness was evaluated by clinical endpoints,
symptom relief, and perceived health status outcomes.
Methods
Study settings. The study design, patient characteristics,
and primary outcomes of the BARI 2D trial were published
previously (9). In brief, 2,368 patients with angiographically
documented stable ischemic heart disease and type 2 diabe-
tes were randomized to receive 1 of the 2 ischemia treat-
ments—prompt revascularization with intensive medical
therapy or intensive medical therapy with delayed revascu-
larization when necessary—and simultaneously randomized
to one of the 2 glycemic treatments—insulin-sensitizing or
insulin-providing drugs to target a hemoglobin A1c level
lower than 7.0%. Before randomization, each consented
patient was evaluated by a cardiologist to determine which
revascularization strategy (coronary artery bypass graft or
percutaneous coronary intervention [PCI]) was appropriate
based on the extent of heart disease determined by coronary
angiography and clinical factors. This intended revascular-
ization strategy was the key stratification variable. Enroll-
ment in the BARI 2D ran from January 1, 2001, to March
31, 2005. Study clinic visits occurred monthly for the first 6
months and every 3 months thereafter. When the trialfollow-up ended on November
30, 2008, the 2,368 participants
were followed for an average of
5.3 years.
Outcomes. CLINICAL ENDPOINTS.
The clinical outcomes included
death from all causes, major car-
diovascular events (defined as the
composite of death, myocardial infarction, and stroke),
cardiac death, and subsequent revascularization procedures.
Vital status was obtained from clinical visits supplemented
with vital status sweeps performed annually. Diagnosis of
myocardial infarction was based on serum cardiac biomark-
ers and core electrocardiography laboratory assessments.
Stroke and cause of death were adjudicated by an indepen-
dent committee.
Revascularization procedural complications included the
occurrence of death and a composite of myocardial infarction
and stroke within 30 days after the procedure, and adverse
events that occurred during the index hospitalization.
ANGINA OUTCOMES. According to the BARI 2D protocol,
angina was assessed at baseline and at every scheduled
follow-up clinic visit. For the present study, we report the
proportion of patients with angina during the past 6 weeks
at the baseline visit and the proportion of surviving patients
with angina reported during the previous year at each annual
follow-up visit. Classic angina was defined as grades I to IV
in the Canadian Cardiovascular Society Classification.
Angina-equivalent symptoms were ischemic chest pain that
resembled angina symptoms but were not classified as stable
or unstable angina.
SUMMARY OF REPEATED HEALTH STATUS MEASURES.
Health status was assessed at baseline and at each annual
follow-up visit by 4 instruments: the Duke Activity Status
Index (DASI) (10), the RAND Medical Outcome Study
Energy/Fatigue Scale (11), RAND Health Distress (12),
and self-rated health (13). DASI is a 12-item questionnaire
that measures the functional capacity in patients with
cardiac disease; the score ranges from 0 (worst) to 58.2
(best). The RAND Energy/Fatigue Scale (hereafter referred
to as Energy) includes 5 items that evaluate how often in the
past month that participants feel energetic or tired. To
measure health distress, we adopted the appropriate items
from the RAND batteries (modified RAND Health Dis-
tress [12], hereafter referred as Health Distress), evaluating
how often the participant feels distressed about health. The
Self-Rated Health score asks the participant to rate their
health in general as excellent, very good, good, fair, or poor.
We transformed the raw scores of the Energy, Health
Distress, and Self-Rated Health to a 0 to 100 scale for
comparison. Higher scores indicated more Energy, better
self-rated health, but worse Health Distress. The health
status measures have been validated in populations with
Abbreviations
and Acronyms
DASI  Duke Activity
Status Index
PCI  percutaneous
coronary interventiondifferent ages and chronic conditions (10,12,14) and are
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Age Study in the BARI 2D Trial August 16, 2011:810–9frequently used in randomized clinical trials for patients
with cardiovascular diseases (15–17).
Statistical analysis. Baseline demographic, clinical, and
ealth status profiles are summarized by 3 age groups
younger than 60 years, 60 to 69 years, or 70 years and
lder), and continuous variables were compared with Spear-
an rank correlation and categorical variables with a
antel-Haenszel chi-square test for trend. The Fisher exact
est was used in age comparisons of revascularization com-
lications for rare events.
Kaplan-Meier survival analysis with log-rank test statis-
ics was used to compare survival by baseline age groups,
ensored at 5 years of follow-up. We compared survival
urves by randomized treatment assignments within each
ge subgroup and tested for an interaction between random-
zed treatment and baseline age group on clinical outcomes.
e estimated the hazard ratio of adverse clinical outcomes
ssociated with increasing age by Cox proportional hazards
egression models. The proportional hazard assumption for
he Cox models was tested, and nonproportional hazards
ere managed by stratification (18).
For the longitudinal analysis of health status, we trun-
ated data at year 4 because an increasing proportion of
atients did not have a year 5 clinical visit due to late
nrollment. The occurrence of classic angina and angina
quivalents at baseline and at each follow-up year was
resented by age groups. We used generalized estimating
quations to model the odds of angina at each follow-up
ear (19). For health status outcomes, we used linear mixed
odels to obtain the averaged effect of age or treatment on
ealth status, accounting for the correlation in repeated
utcome measures within each participant (20,21). The
odeling approaches are summarized in the supplementary
ppendix of the report.
Multivariate models for both survival and longitudinal
nalysis were constructed to adjust for trial design variables
ncluding randomized treatment, important baseline clinical
actors, and reported potential confounders in the associa-
ion between age and health outcomes, including sex and
ardiovascular complications (22). Treatment effect was
nalyzed based on the intention-to-treat principle; the
nteractions between baseline age and randomized treat-
ent, intended revascularization method, and follow-up
ime were tested in all multivariate models. For subgroup
nalyses and effect modification, a 2-sided alpha level of
.01 was used to control multiple comparisons. We exam-
ned the linear assumption and model fit (20) (summarized
in the Online Appendix). All analyses were performed using
SAS version 9.0 (SAS Institute, Cary, North Carolina).
Results
Baseline characteristics. The mean age of the 2,368 en-
rolled participants at baseline was 62.4 years, with a maxi-
mum age of 89.8 years. Of the 2,368 BARI 2D patients,
514 (21.7%) were age 70 years or older, and 38 patients c(1.6%) were 80 years or older. Patients younger than 60
years of age were more likely to be smokers and to have a
higher body mass index and lower systolic blood pressure
but higher diastolic blood pressure and higher prevalence of
myocardial infarction, whereas patients older than 60 years
of age had a greater prevalence of cardiovascular disease
history, such as hypertension, congestive heart failure, and
stroke, and more often had bypass surgery selected as the
intended method of coronary revascularization (Table 1).
Older patients entered the study with longer duration of
diabetes and higher prevalence of hypoglycemic episodes and
neuropathy. It is notable that patients older than 70 years of
age had lower mean hemoglobin A1c level (7.1%), which was
close to the glycemic control target in the BARI 2D, than
younger age groups. At baseline, older age groups were
associated with a lower DASI, but higher Energy, Health
Distress, and self-rated health scores.
Age and randomized ischemia treatments. CLINICAL
OUTCOMES. Over an average of 5.3 years of follow-up,
dverse event rates increased by older age for death (p 
.001) and major cardiovascular events (p  0.001), but not
or cardiac death (p  0.31) (Table 2). Among patients
ppropriate for PCI, those who were younger than 60 years
f age had a higher rate of subsequent procedures (p 
.014). In Cox regression analysis, the effect of the assigned
rompt revascularization strategy on clinical outcomes did
ot differ by age. Although medical therapy was associated
ith lower mortality than prompt revascularization for
atients between 60 and 69 years of age, the interaction
etween age and revascularization was not significant (p 
.99). For patients 70 years of age or older, the effect of
rompt revascularization did not significantly differ from
hat of medical therapy for any of the 5-year clinical event
utcomes. Age did not interact with revascularization for
ajor cardiovascular events (p  0.081) (Fig. 1), cardiac
eath, or subsequent procedures (Table 2). The interactions
etween age and assigned treatment were nonsignificant
verall and within each of the intended revascularization
trata. For example, the significance of the interaction
etween age and revascularization for the mortality outcome
as p 0.11 in the coronary artery bypass graft stratum and
 0.28 in PCI stratum.
All age groups had low rates of revascularization proce-
ural complications. Patients 70 years or older who under-
ent bypass surgery experienced more cardiogenic shock or
ypotension and more congestive heart failure or pulmonary
dema during the index hospitalization compared with
ounger patient groups (Table 3).
ongitudinal angina outcomes. At baseline, classic angina
as more common among younger patients than among
lder patients (p  0.001). After treatment, angina was
educed significantly (p  0.001), with a similar degree of
eduction in all age groups (odds ratios for year 4 angina vs.
aseline angina were between 0.18 and 0.26 for all age
roups). Consequently, classic angina continued to be more
ommon among younger patients than among older patients
l
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August 16, 2011:810–9 Age Study in the BARI 2D Trialthroughout follow-up (p  0.05). In contrast, the preva-
ence of angina-equivalent symptoms was similar in all age
Baseline Characteristics by AgeTable 1 Baseline Characteristics by Age
Age <6
(n  9
Trial parameters
CABG strata 26
Early revascularization 51
Insulin sensitizing 51
Demographic characteristics
Male 70
Race
White 58
Black 19
Hispanic 15
Other 5
Region of world
United States 62
Canada 15
Mexico 4
Brazil 15
Czech Republic/Austria 2
Current cigarette smoker 20
Body mass index, kg/m2 32.6
Sitting SBP, mm Hg 128.5
Sitting DBP, mm Hg 76.8
Cardiac clinical history
Myocardial infarction 35
Angina category
None/angina equivalent only 33
Stable CCS1/CCS2 44
Stable CCS3/CCS4/unstable 21
No. of diseased myocardial region (50%)
0 or 1 36
2 36
3 27
Left ventricular ejection fraction 50% 16
Hypertension 79
Congestive heart failure 4
Stroke 6
Noncoronary artery disease 19
Chronic obstructive pulmonary disease 4
Previous PCI 19
Previous CABG 5
Diabetes characteristics
Duration of diabetes, yrs 8.5
Hemoglobin A1c 8.0
Currently taking insulin 28
Hypoglycemic episode 20
Neuropathy: clinical MNSI 2 44
Health status
DASI (0–58.2) 19.7
Energy score (0–100) 48.7
Health distress score (0–100) 47.2
Self-rated health (0–100) 34.8
Values are % or mean SD. *Continuous variables with Spearman rank co
CABG coronary artery bypass graft; CCS Canadian Cardiovascula
MNSI  Michigan Neuropathy Screening Instrument; PCI  percutaneroups at baseline. After treatment, the prevalence ofangina-equivalent symptoms decreased to a similar extent in
all age groups (odds ratios for year 4 vs. baseline were
Age 60–69 Yrs
(n  915)
Age >70 Yrs
(n  514) p Value*
37.3 33.1 0.0015
49.1 48.2 0.28
47.8 50.6 0.46
73.0 65.4 0.11
0.001
70.4 71.2
14.5 15.4
10.9 9.3
4.2 4.1
0.026
60.2 70.6
14.5 14.4
3.7 1.8
17.8 10.1
3.7 3.1
10.4 2.3 0.001
31.4 5.6 30.6 5.0 0.001
133.3 20.0 134.8 19.5 0.001
74.7 10.7 70.0 10.6 0.001
30.1 30.1 0.031
0.001
42.0 45.3
41.0 41.2
17.0 13.4
0.046
31.0 32.9
35.9 35.6
33.2 31.5
17.9 17.8 0.63
84.8 84.2 0.007
7.6 8.2 0.0071
11.6 12.7 0.001
26.4 26.5 0.001
5.8 5.5 0.16
19.2 19.8 0.94
6.8 8.0 0.034
11.2 8.7 12.6 9.7 0.001
7.6 1.6 7.1 1.2 0.001
28.2 25.9 0.31
23.3 25.3 0.048
52.3 57.0 0.001
19.2 13.5 17.0 11.8 0.018
53.1 23.0 53.2 21.8 0.001
37.5 24.7 33.4 23.2 0.001
39.9 21.2 43.3 20.9 0.001
and categorical variables with a Mantel-Haenszel chi-square test for trend.
ty; DASI Duke Activity Status Index; DBP diastolic blood pressure;
ronary intervention; SBP  systolic blood pressure.0 Yrs
39)
.8
.0
.8
.5
.6
.8
.9
.8
.3
.5
.5
.0
.7
.1
6.6
19.9
11.4
.0
.5
.7
.8
.1
.0
.8
.9
.4
.8
.3
.6
.1
.9
.2
7.5
1.8
.6
.9
.7
14.2
23.2
25.4
22.0
rrelationbetween 0.29 and 0.32), and consequently angina-
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Age Study in the BARI 2D Trial August 16, 2011:810–9equivalent symptoms were present to a similar degree
among all age groups at follow-up.
Patients assigned to prompt revascularization were sig-
nificantly less likely to have classic angina symptoms at the
1-year follow-up compared with those assigned to medical
therapy. The observed treatment differences were larger and
more significant in the younger patient groups (Fig. 2);
however, the effect of prompt revascularization on classic
angina at 1 year did not vary significantly by age group
(interaction p  0.62). Using longitudinal mixed models,
prompt revascularization resulted in a greater relief of classic
angina than medical therapy in all age groups over the
follow-up period (revascularization vs. medical therapy,
odds ratio: 0.63, p  0.001 overall; 0.61, p  0.001 for ages
ounger than 60 years; 0.60, p  0.001 for ages 60 to 69
ears; and 0.71, p  0.032 for ages 70 years and older).
ssignment to prompt revascularization also resulted in a
ower occurrence of angina equivalents in all age groups
revascularization vs. medical therapy, odds ratio: 0.77, p 
0.001 overall; 0.74, p  0.009 for ages younger than 60
years; 0.80, p  0.047 for ages 60 to 69 years; and 0.77,
p  0.076 for ages 70 years and older). There was no
significant interaction between age and randomized cardiac
treatment for classic angina (p  0.98) or for angina
equivalents (p  0.86).
Longitudinal health status outcomes. A total of 2,163
patients with at least 1 follow-up health status measurement
were included in the longitudinal analysis for health status.
All 4 health status measures improved significantly from
baseline to year 1 across the age categories (Fig. 3). After the
first year, however, all 4 health status measures worsened
over subsequent follow-up, and the rate of decline for
DASI, Energy, and Health Distress was significantly
greater among older patients (p  0.01) (Table 4). After 4
years of follow-up, functional activity status (DASI) was
significantly better compared with baseline for patients
younger than 60 years of age at entry but was significantly
worse than baseline for patients age 70 years or older.
Energy scores were significantly better at 4 years compared
with baseline for patients younger than 70 years of age at
5-Year Event Rate by Baseline Age Groups and Randomized CardiaTable 2 5-Year Event Rate by Baseline Age Groups and Random
Clinical Endpoints
Age <60 Yrs
REV
(n  479)
MED
(n  460) (
Death, % 6.7 9.2
Death/MI/stroke, % 19.9 19.1
Cardiac death, % 4.2 5.8
Subsequent procedure, % by stratum
Among intended CABG patients (n  763) 14.1 43.6
Among intended PCI patients (n  1,605) 33.5 48.3
*p value for comparing survival curve across age categories. †p value for interaction obtained from
angina status.
MI  myocardial infarction; MED  medical therapy; REV  revascularization; other abbreviatistudy entry but not for patients 70 years of age or older.Health Distress and Self-Rated Health were better at 4
years than at baseline for all age groups (Fig. 3).
The effect of the assignment to prompt revascularization
on health status did not differ by baseline age (Table 4); the
significance of the interactions were p  0.56 for DASI,
p 0.87 for Energy, p 0.11 for Health Distress, and p
0.064 for Self-Rated Health. Averaged over age and
follow-up years, prompt revascularization was associated
with a small but significant increase in DASI score, Energy,
and Self-Rated Health in multivariate models (Table 4).
There was no significant interaction between age and the
intended method of revascularization on health status out-
comes. In the multivariate models, older age was associated
with a steeper decline for DASI, Energy, and Health
Distress over time (p  0.01) (Table 4); this age by time
interaction is illustrated in Figure 4.
Age and randomized glycemic treatments. Clinical out-
comes after randomization to the insulin-sensitizing and
insulin-providing strategies were also similar in all age
groups: the interaction p values were 0.44 for death, 0.67 for
major cardiovascular death, 0.85 for cardiac death, and 0.72
for subsequent procedures. The effect of randomization to
glycemic treatment on health status did not differ by age; the
interaction p values were 0.13 for DASI, 0.19 for Energy,
0.11 for Health Distress, and 0.31 for self-rated health.
Discussion
Prompt revascularization versus initial medical therapy and
insulin-sensitizing versus insulin-providing therapy resulted in
similar clinical outcomes of death, major cardiovascular events,
and cardiac death among younger patients and among older
patients. Over 4 years of follow-up, prompt revascularization
was associated with a 39% reduction in odds of classic angina
for patients younger than 60 years of age at baseline, 40% for
patients between 60 and 69 years of age, and 29% reduction for
patients older than age 70 years compared with initial medical
therapy. The improvements in health status associated with
prompt revascularization were also independent of age. Over-
all, younger patients were able to maintain initial improve-
atmentCardiac Treatment
ge 60–69 Yrs Age >70 Yrs p Value
49)
MED
(n  466)
REV
(n  248)
MED
(n  266)
Age
Trend*
Age and REV
Interaction†
9.6 16.5 22.6 0.001 0.99
21.6 27.7 36.6 0.001 0.081
4.4 5.9 8.1 0.31 0.98
33.5 2.8 47.3 0.33 0.10
39.3 27.1 39.7 0.014 0.36
ression models controlled for geographic region, intended revascularization method, and baseline
n Table 1.c Treized
A
REV
n  4
14.6
23.3
7.9
7.1
27.5
Cox regments in health status over the 4 years of follow-up, whereas
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August 16, 2011:810–9 Age Study in the BARI 2D Trialolder patients experienced a decline in health status during
follow-up. Therefore, although older patients have higher rates
of death and major cardiovascular events than younger patients,
Figure 1 Five-Year Survival Free of
Major Cardiovascular Events
Kaplan-Meier estimates comparing patients randomized to prompt revascular-
ization (REV) (solid red line) versus medical therapy (MED) (dashed black line)
stratified by baseline age category: age younger than 60 years, age 60 to 69
years, and age 70 years and older.the comparative treatment effectiveness of ischemia treatmentstrategies and glycemic control strategies, assessed by clinical
outcomes, symptom relief, and health status, did not differ by age.
Previous randomized trials comparing revascularization
with medical therapy for patients with stable ischemic heart
disease have reported similar effects of revascularization for
different age groups. In the COURAGE (Clinical Out-
comes Utilizing Revascularization and Aggressive Drug
Evaluation) trial, in which 2,287 patients with stable coro-
nary artery disease were randomized to receive either PCI or
medical therapy, the effect of revascularization on mortality
and other clinical outcomes did not differ by age groups
(23). The CASS (Coronary Artery Surgery Study) reported
similar outcomes with bypass surgery versus medical therapy
for survival in various age groups of patients with stable
angina (3). The European Coronary Surgery study reported
a trend of greater survival benefit for bypass surgery over
medical therapy in patients older than 53 years at baseline,
but the effect modification between age and treatment was
not statistically significant (24).
In the PROACTIVE (Prospective Pioglitazone Clinical
Trial in Macrovascular Events) (25) and MICRO-HOPE
(Heart Outcomes Prevention Evaluation) trials (26), which
examined the effects of diabetes therapies and hypertension
therapies, respectively, in patients with type 2 diabetes, there
was no age difference in the effect of active treatment versus
placebo on death and cardiovascular complications. To our
knowledge, the present study is the first to simultaneously
evaluate whether age modifies the effect of treatment strat-
egies for stable coronary heart disease and for type 2
diabetes. Our findings showed similar clinical outcomes
with prompt revascularization versus medical therapy and
with insulin-sensitizing versus insulin-providing therapy for
younger and older participants. The findings were consis-
tent with those of previous clinical trials.
The complication rates for both revascularization proce-
dures were very low in the BARI 2D. However, the study
population is largely composed of middle-aged or young
elderly individuals. Patients with left main coronary artery
stenosis50% or class III or IV heart failure were excluded.
For patients receiving coronary artery bypass graft as their
assigned revascularization procedure, a higher prevalence of
procedural complications including congestive heart failure
or pulmonary edema and cardiogenic shock or hypotension
was observed in patients older than age 70 years at baseline.
An inverse association between age and the subsequent proce-
dure rate was observed in the present study as well as the
original BARI trial (27). Potential reasons for this phenome-
non may be that older patients were less willing to undergo
another procedure or they had a greater tolerance of angina
symptoms (28). Moreover, there may be some survival bias in
that the sickest older patients were “censored” from the data for
subsequent procedure analysis due to death.
Over the 4 years of follow-up, prompt revascularization
was the preferable treatment strategy for relief of classic
angina among older and younger patients. For patients with
heart disease who were suitable for bypass surgery, revascu-
and 2.
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Age Study in the BARI 2D Trial August 16, 2011:810–9larization reduced the odds of classic angina by 58%
compared with medical therapy. The effect of revasculariza-
tion on angina-equivalent symptoms did not differ by age,
indicating that revascularization was preferable for reducing
atypical angina in patients of all ages.
Besides clinical endpoints and cardiac symptoms, this
study evaluated how age and treatment affect patients’
perceived health status over time. At baseline, older partic-
Revascularization Procedural Complicationsin P tients Randomized to Prompt RevascularizTable 3 Revascularization Procedural Compin Patients Randomized to Prompt
Age <60 Yrs
CABG (n  343) n 124
Death 0.8
MI/stroke 3.2
CHF/pulmonary edema 0.8
Cardiogenic shock/hypotension 4.0
Hemorrhage/bleeding† 1.6
Dementia/coma 0.0
Respiratory‡ 3.2
Renal failure 1.6
Other 1.6
PCI (n  752) n 323
Death 0.6
MI/stroke 4.0
CHF/pulmonary edema 0.3
Cardiogenic shock/hypotension 1.6
Hemorrhage/bleeding 0.6
Renal failure 0.3
Other 0.3
Values are %. *Fisher exact test results. †Including hemorrhage requ
requiring transfusion. ‡Contain respiratory failure including noncardia
in place at least 3 days post-surgery.
CHF  congestive heart failure; other abbreviations as in Tables 1
Figure 2 Classic Angina by Age Group and Randomized Treatm
The comparison of angina rates for patients randomized to REV (blue bars) versus
cance: *0.01  p  0.05 and **p  0.01. The significance of the interactions b
1 year, and p  0.23 at 3 years. Abbreviations as in Figure 1.ipants had lower functional capacity but higher perceived
health status. After 1 year in the BARI 2D trial, the 4 health
status measures improved significantly in every age group.
Over subsequent follow-up, however, these initial gains
eroded faster for older patients than for younger patients.
Nevertheless, even the oldest patients improved compared
with baseline in the levels of angina, Health Distress, and
Self-Rated Health.
ons
cularization
Age 60–69 Yrs Age >70 Yrs p Value*
n 148 n 71
2.7 0 0.29
3.4 4.2 0.86
0 2.8 0.055
2.0 12.7 0.0049
5.4 5.6 0.20
2.0 4.2 0.067
4.1 7 0.49
0 0 0.17
1.4 1.4 1.00
n 270 n 159
0.7 0 0.83
2.2 3.1 0.44
0 0 1.00
1.5 1.3 1.00
1.5 0 0.32
0 0 1.00
1.1 2.5 0.091
ansfusion, reoperation for bleeding, or event other than hemorrhage
nary edema and adult respiratory distress syndrome; chest tubes left
(red bars) within age group at baseline, 1 year, and 3 years; statistical signifi-
age group and prompt revascularization is p  0.40 at baseline, p  0.62 atationlicati
Revas
iring tr
c pulmoent
MED
etween
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August 16, 2011:810–9 Age Study in the BARI 2D TrialThe association between age and health status has been
assessed in a few randomized trials comparing revascu-
larization and medical therapy. In the second Random-
ized Intervention Treatment of Angina study, the effect
of age was independent of assignment to PCI or medical
therapy (29). The TIME (Trial of Invasive Versus
Medical Therapy in Elderly Patients With Chronic
Symptomatic Coronary Artery Disease) compared the
effect of revascularization versus medical therapy on
Figure 3 Estimated Mean Health Status by Age Group and Tim
Estimates for Duke Activity Status Index (DASI), Energy, Health Distress, and Self-
group (younger than 60 years [blue diamonds]; 60 to 69 years [red circles]; 70 y
baseline age group and follow-up time, random site effect and missing data patter
Statistical significance: *0.01  p  0.05 and **p  0.01.
Health Status Outcomes During BARI 2D Follow-Up Based on MultTable 4 Health Status Outcomes During BARI 2D Follow-Up Ba
Baseline Variables
(
Est
Age at baseline (per 10 yrs) 1.63
Follow-up time (per 1 yr) 0.66
Age*: follow-up time interaction (per 10 yrs of age and 1 yr of follow-up) 0.33
REV vs. MED 1.24
IS vs. IP 0.51
CABG stratum 0.61
Baseline health status measure 0.51
*Model controlled for random site effect, and baseline variables including angina status, insulin
congestive heart failure, history of stroke, history of noncoronary artery disease, clinical evidence of neur
BARI 2D  Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes; Est Estimated Regreshealth-related quality of life in 305 patients who were
older than 75 and with chronic ischemic diseases. At
6 months of follow-up, the improvement in symptom
relief and quality of life was greater for revascularization
than for medical therapy (17), but the preferable results
associated with revascularization disappeared at 1 year
follow-up (1). In our trial, with an extended follow-up of
4 years, prompt revascularization treatment for heart
disease resulted in a slightly greater health status im-
Health are based on longitudinal mixed models accounting for baseline age
nd older [green triangles]), categorical follow-up time, the interaction between
estimated health status at each follow-up year is compared with baseline.
ble Regression Models*n Multivariable Regression Models*
)
Energy
(0–100)
Health Distress
(0–100)
Self-Rated Health
(0–100)
Value Est p Value Est p Value Est p Value
.001 0.13 0.75 1.80 0.001 0.48 0.23
.001 0.26 0.061 0.16 0.34 0.21 0.19
.0015 0.89 0.001 0.91 0.001
.0012 1.16 0.043 0.36 0.59 1.72 0.0066
.18 0.31 0.58 0.52 0.42 1.01 0.11
.18 1.60 0.018 2.24 0.0038 3.08 0.001
.001 0.43 0.001 0.41 0.001 0.40 0.001
x, body mass index, smoking, history of hypertension, history of myocardial infarction, history ofe
Rated
ears a
n. Theivariased o
DASI
0–58.2
p
0
0
0
0
0
0
0
use, se
opathy, missing data patterns.
sion Coefficient; IP  insulin providing; IS  insulin sensitizing; other abbreviations as in Table 2.
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Age Study in the BARI 2D Trial August 16, 2011:810–9provement than medical therapy, and the beneficial effect
is similar for older and younger patients.
Previous randomized trials for treatment of coronary
artery disease have reported that health status changes start
with a significant initial improvement from baseline and
gradually wanes during follow-up years (25,30). We ob-
served a similar trajectory. In addition, our study demon-
strates that age modifies the changes in health status over
time such that the decline in health status was greater in
older than younger patients.
At baseline, greater angina severity was significantly
associated with lower health status. The reduction in angina
during follow-up may contribute to the overall improve-
ment in participants’ health status. It has been shown that
among patients with similar health conditions, older indi-
viduals report better perceived health status than younger
individuals (31). Likewise, we observed that older patients
have better perceived health than younger patients, even
with less capacity to perform daily tasks. Older participants
in BARI 2D had lower body mass index, better diabetes
control, and a lower proportion of current smoking and
classic angina at baseline. The good disease self-
management and lower classic angina prevalence in older
participants may contribute to their better perceived health
status. Because better self-rated health is associated with
lower mortality in older individuals (32), it is possible that a
positive attitude toward health contributes to the good
condition of our elderly patients.
Study limitations. The BARI 2D included patients with
Figure 4 DASI by Baseline Age and Follow-Up Time
Estimates and interpretation of the results from the Duke Activity Status Index (DA
that include an interaction between baseline age and follow-up time.moderate heart disease and type 2 diabetes suitable for eithertreatment strategy for ischemia management and glycemia
control. Consequently, the study population might not fully
represent all patients with heart disease and type 2 diabetes.
Information on the occurrence of arthritis or dementia was not
collected, which could contribute to the deterioration of health
status. The longitudinal analysis was limited to patients with at
least 1 follow-up health status measure, and patients without
any follow-up health status information might be a concern.
However, when we compared the results with those in sensi-
tivity analyses in which missing health status outcomes were
imputed using multiple imputations, the associations between
age and health status outcomes were similar in the original and the
expanded dataset. This suggests that the missing data did not
substantially alter our study results. In addition to the quality data
and study design in the BARI 2D, an additional strength of the
present study was that older patients received revascularization
according to treatment protocol. The underuse of invasive treat-
ment strategies for older patients was minimized to enable the
accurate investigation of treatment effect by age.
Conclusions
Among patients with documented stable heart disease and
type 2 diabetes, the relative beneficial effects of a strategy of
prompt revascularization versus initial medical therapy with
delayed revascularization and insulin-sensitizing versus
insulin-providing drug therapy on clinical endpoints, symp-
tom relief, and perceived health status outcomes do not vary
ltivariate longitudinal mixed modelSI) muby age. Health status improved significantly after treatment
11
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
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August 16, 2011:810–9 Age Study in the BARI 2D Trialfor all ages, and this improvement was sustained longer
among younger patients.
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